Audit: QRS - Green Tea for Health & Longevity

Audit conducted on 05/08/2026 19:06 using AI4L + evidence-mcp / Opus 5

Iterations

Summary

Items Count
Total 91
Passed 81
Failed 0
N/A 10
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 Protocol values (3–5 cups, 240 mL, 240–500 mg catechins, 75–350 mg caffeine, 70–80 °C for 2–3 minutes, 250–500 mg EGCG with meals, 500–1000 mg of a 50% extract, split dosing) trace to ER lines 449, 451, 461, 463. Time-to-effect values trace to ER line 510. All 11 monitoring targets are verbatim from the ER biomarker table (ER 538–548); cadence matches ER 532–534.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 The ER’s two “⚠️ Conflicted” markers are carried through as “, conflicted” in benefits_medium (cancer incidence) and risks_speculative (exercise adaptation blunting), preserving the ER’s hedge without the banned emoji.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Severity classes are carried verbatim: “absolute contraindication” (bortezomib), “absolute avoidance of co-administration” (nadolol), “caution, monitor”, “avoid combining”. Nothing upgraded or downgraded relative to ER 401–421.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Every gate item derives from the ER Key Interactions & Contraindications section. HLA-B*35:01 carriage and ferritin below 30 ng/mL appear in the Contraindications gate because ER line 421 lists both there, not because they were lifted from Risk-Modifying Factors.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 The QRS contains no PMIDs, no NCT identifiers, no expert names and no brand names.
1.6 The QRS does not introduce new attributions. 🟢 No attributions of any kind are present.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Measured, non-promotional register throughout; the ER’s own hedging (“unsettled”, “conflicted”) is retained.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Quantified targets and ranges with plain-language framing in the at-a-glance.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Content is stated as ranges and observations rather than instructions to a patient.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 Gate and cadence entries are bare noun phrases derived from the ER’s published-protocol language, not directives.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 No instance of “recommend”, “advise”, “should” in the QRS’s own voice.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person pronouns in any populated variable.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms are confined to the Monitoring and gate sections where they are the ER’s own biomarker and drug names; expansions are kept (e.g., “ALT (alanine aminotransferase)”).
2.8 Information is presented in a concise and very compact manner 🟢 The ER’s 15 benefit and 11 risk subsections are reduced to four one-line tiers each; ER full-sentence monitoring rationales are reduced to short phrases.
2.9 It DOES NOT address the reader directly 🟢 Confirmed across all populated spans.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Functional-range biomarker targets and a genotype/ferritin-aware contraindication list address exactly this audience.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Baseline and serial liver panels, weekly home blood pressure, meal separation and an 8–10 hour caffeine cutoff are all retained.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 No simplification down to general-population advice; the full monitoring burden is presented.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 The at-a-glance explicitly separates the beverage’s small consistent effects from the extract’s added effect and liver risk, which is the decision this audience faces.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 “anti-aging” does not appear anywhere in the QRS.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 “brewed cups”, “extract”, “catechins”, “hepatocellular injury”, “iron-deficiency anaemia” — all formal and all the ER’s own terms.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All headings, gate titles, tier labels and the Marker/Target/Why column headers match the template byte-for-byte.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All 38 template variables are present. The repeatable marker_#_* and qualitative_item_# placeholders are correctly expanded to marker_1–11 and qualitative_item_1–5.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 A structural diff against the template shows no modification outside the variable spans and the metadata block — CSS, header markup, <span website="…"> hooks and the footer disclaimer are untouched.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No source ER section that feeds the QRS is empty.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 “Standard beverage protocol”, “Standard extract protocol”, “Best time of day” match ER 449/451/459; all five qualitative labels match ER 552–556 verbatim; all 11 marker names match the ER table’s Biomarker column.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 The three Time-to-effect labels are drawn from the ER’s own phrasing in line 510 (“Blood pressure and lipid changes”, “Body composition changes”, “The acute cognitive and mood effect”), not invented.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 Zero emoji characters in the file; tiers are rendered via <strong> labels and the card colour classes.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 The template’s A4 print rules are intact and every over-budget section was condensed rather than carried over: the ER’s 11-bullet interaction section became 3 gate items plus 8 caution items with example-drug lists trimmed (rosuvastatin, edoxaban, dabigatran, phenylephrine, naproxen, ashwagandha, comfrey dropped per 9.5), the ER Conclusion became 59 words, and full-sentence monitoring rationales became short phrases.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Lines 2–14; it is the first element after the doctype.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 Opening --- at line 3, closing --- at line 13; the preceding descriptive text sits on line 2.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment; no metadata value is echoed into the page body.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration: "00:04" is quoted, and it contains a colon; all other values are bare and untrimmed of nothing.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename: green_tea_2026-0805-1446_Opus_ER.md (line 4).
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.7.02 (line 5), matching the QRS.md version badge.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 qrs_creation_date: 2026-0805-1829 (line 6).
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 qrs_creator_ai_nickname: Opus (line 7).
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 “Opus” — single word, no version.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 qrs_creator_ai_fullname: Opus 5 (line 8).
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 5” — nickname plus version, no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 qrs_filename: green_tea_2026-0805-1446_Opus_QRS.html (line 9), matching the file on disk.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 <title>Green Tea for Health &amp; Longevity - Quick Reference Sheet</title> (line 22); ampersand correctly entity-encoded.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 “Green Tea for Health & Longevity” (line 417), matching ER frontmatter canonical_topic.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 2026-0805-1829 → “08/05/2026” (line 421).
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 “Opus 5” (line 425), matching the frontmatter value.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 The header carries only the title and the template’s standard subline; the ER’s alternate_names list is not surfaced.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Condenses all three Conclusion paragraphs (ER 584–588) into the beverage/extract decision.
7.2 [at_a_glance] is no longer than 60 words 🟢 59 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Cholesterol/blood pressure/body fat and heart-disease death plus cognitive decline → ER 584; cancer unsettled → ER 584; extract liver injury at added effect → ER 586 and 588.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 No acronyms; “slower decline in thinking” replaces “cognitive decline” and “blood cholesterol” replaces the lipid nomenclature.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial names, years or sample sizes.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No numeric estimates of any kind.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All three items map to ER lines 401, 403 and 421.
8.2 [stop_items] represent the Contraindications from the ER 🟢 The ER’s two absolute entries (bortezomib, nadolol) plus the “Populations who should avoid concentrated extract” bullet are the only ER items marked as contraindications, and all three are present.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Three <li> elements inside the stop_items span (lines 542–544).
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 The ER’s OATP1A2 and boronic-acid mechanisms and its “Mitigation:” clauses are stripped; no dash-introduced trailing clause remains.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 “(absolute contraindication)”, “(absolute avoidance of co-administration)”, “(any Child-Pugh class)”, “ALT above twice the upper limit of normal” and “ferritin below 30 ng/mL” are all retained.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER’s Key Interactions & Contraindications section uses no ranking notation; thresholds are written out in words (“above twice the upper limit of normal”).
8.7 If no [stop_items] are present the section is left empty N/A Three stop_items are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All eight items map to ER lines 405–419.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 Eight of the ER’s eleven bullets appear here; the three routed to Contraindications (nadolol, bortezomib, populations to avoid extract) are correctly excluded and not duplicated.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Eight <li> elements inside the caution_items span (lines 552–559).
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 OATP1B1/dihydrofolate-reductase mechanisms, INR-recheck details and every “Mitigation:” clause are stripped; no dash-introduced trailing clause remains.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Every bullet keeps its severity class (“caution, monitor”, “caution, timing separation”, “avoid combining”) and a representative example-drug list; lists were trimmed for the one-page budget but never dropped entirely.
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A No ranking notation appears in the ER’s interaction bullets.
9.7 If no [caution_items] are present the section is left empty N/A Eight caution_items are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Drawn from ER Therapeutic Protocol lines 449, 451, 459, 461 and 463.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Beverage dose, extract dose, and timing — the ER’s two named “standard” protocols plus its “Best time of day” bullet. Fed dosing, the ER’s single most important safety modifier, is folded into action_2_value (“with meals”).
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER provides well over three actionable aspects and all three sets are populated.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All nine action variables carry substantive ER-derived content; no placeholder text remains.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Blood pressure/lipids (4–12 weeks), body composition (≥12 weeks) and acute cognitive/mood (30–60 minutes), all from ER line 510. The fourth aspect — decades-long disease-risk associations — is folded into time_3_sub rather than dropped.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Ordered High → High → Medium: lipids and blood pressure and body composition are ER High-tier benefits, acute cognitive performance is Medium-tier.
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER describes four distinct time-to-effect aspects and all three sets are populated.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 All nine time variables carry ER-derived content; no placeholder text remains.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides an explicit “Time to effect” bullet (line 510), so the section is correctly retained.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 All 15 benefit headings from ER lines 170–281 are represented in the matching tier.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four spans present and populated (lines 521–532).
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Each item is the ER subsection heading only; every “Magnitude:” line and all mechanistic prose is dropped. The single retained qualifier, “, conflicted”, is part of the ER’s own heading and removing it would strengthen the claim contrary to 1.3.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses appear in any benefits span.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four ER benefit tiers contain items, so no span needs hiding.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 All 11 risk headings from ER lines 308–379 are represented in the matching tier.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four spans present and populated (lines 571–582).
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Each item is the ER subsection heading only; the 6.7% ALT-elevation figure, the 800 mg EFSA threshold and all mechanistic prose are dropped.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses appear in any risks span.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four ER risk tiers contain items, so no span needs hiding.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Rows correspond one-to-one with the ER biomarker table at lines 536–548.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All 11 ER biomarkers present — ALT, AST, alkaline phosphatase, total bilirubin, ferritin, apolipoprotein B, LDL cholesterol, HbA1c, fasting glucose, hs-CRP and blood pressure — with their Optimal Functional Range values reproduced verbatim.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Line 723 reproduces the full cadence from ER 532–534, including the brewed-tea-only fallback.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Drawn from the qualitative-marker bullets at ER lines 552–556.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All five present: sleep quality and latency, calm alertness versus jitteriness, afternoon energy stability, digestive tolerance, and any symptom of liver injury — with the ER’s bold labels verbatim.

Issues 05/08/2026 19:06

Pass rate 100.00%. No issues found.

Issues 05/08/2026 19:03

  1. 10.4 — Protocol cell imports risk-mitigation text: [action_1_sub] (line 450) ends with “cooled below 60 °C”, which comes from the ER Risk Mitigation Strategies section (line 440) rather than the ER Therapeutic Protocol section, whose “Brewing parameters” bullet (line 463) specifies only “Water at 70–80 °C for 2–3 minutes”.

Fixes 05/08/2026 19:03

  1. 10.4 — Protocol cell sourced from Protocol section: Replaced the trailing “cooled below 60 °C” in [action_1_sub] with “for 2–3 minutes”, so the cell now reads “Brewed at 70–80 °C for 2–3 minutes.” and draws only on the ER Therapeutic Protocol “Brewing parameters” bullet.

Issues 05/08/2026 18:56

  1. 4.5 — QRS exceeds one A4 page: Estimated rendered height is roughly twice the A4 budget; the Key Interactions gate wraps to about 21 lines (the over-the-counter item at 162 characters and the additive-effects item at 160 characters each wrap to four lines), the Contraindications gate carries a 411-character single-item run-on, and the Monitoring table adds 11 rows plus a 327-character cadence paragraph.

Fixes 05/08/2026 18:56

  1. 4.5 — Key Interactions gate condensed: Trimmed the example drug lists in the Key Interactions gate to their leading representatives (statins to atorvastatin/simvastatin, anticoagulants to apixaban/rivaroxaban, decongestants to pseudoephedrine, NSAIDs to ibuprofen, stimulants to methylphenidate, additive-effect supplements to berberine/chromium/beetroot/garlic/fish oil, additive-liver-risk supplements to Garcinia cambogia/kava/high-dose niacin), reducing the gate from about 21 wrapped lines to about 16 while retaining at least two named examples per class.
  2. 4.5 — Contraindications run-on shortened: Replaced “prior reaction to green tea extract or other drug-induced liver injury” with the ER’s own shorter formulation “prior herbal or drug-induced liver injury” in the avoid-concentrated-extract population item, without dropping any listed population or threshold.
  3. 4.5 — Monitoring “Why” cells tightened: Compressed six over-long rationale cells (AST, alkaline phosphatase, total bilirubin, apolipoprotein B, HbA1c, hs-CRP) to single-line equivalents, e.g. “Atherogenic particle count; the most reliable cardiovascular benefit” to “Atherogenic particle count; most reliable benefit”. All 11 biomarkers and their targets are unchanged.

Issues 05/08/2026 18:41

  1. 4.5 / 2.8 — Sheet exceeds one A4 page: The QRS body carries 902 rendered words against a 414–547 word range in comparable published QRSes, driven by monitoring_cadence (77 words), the three action_#_sub cells (83 words), the five qualitative_item_# entries (73 words), the 11 monitoring why cells (92 words) and the long “Populations who should avoid concentrated extract” gate item (60 words); the sheet overflows onto a second page instead of being condensed.

Fixes 05/08/2026 18:41

  1. 4.5 / 2.8 — Protocol sub-cells condensed: The three action_#_sub cells were cut from 83 to 53 words by dropping restated rationale (“for fat oxidation”, “for the cognitive effect”, “when caffeine is unwanted”) and the redundant 2–3 minute steep time, while keeping every dose, volume and temperature figure.
  2. 4.5 / 2.8 — Time-to-effect sub condensed: time_3_sub was shortened from “Acute caffeine-theanine effect, not cumulative. Disease-risk associations reflect years to decades and cannot be perceived.” to a single clause ending at “years to decades”.
  3. 4.5 / 2.8 — Monitoring cadence condensed: monitoring_cadence was cut from 77 to 52 words, keeping every interval (8 weeks, 6 months, 12 weeks, annual, 6-monthly subgroups, weekly blood pressure) but dropping the restated preamble and the “at ordinary intakes” clause.
  4. 4.5 / 2.8 — Monitoring rationales tightened: Six of the eleven marker_#_why cells were shortened (e.g. “Tracks green tea’s most reliable cardiovascular benefit — the atherogenic particle count” → “Atherogenic particle count; the most reliable cardiovascular benefit”), bringing the column to one wrapped line per row.
  5. 4.5 / 2.8 — Qualitative entries reduced to fragments: The five qualitative_item_# entries were cut from 73 to 58 words by replacing the “whether … has changed since …” clauses with bare marker fragments; the ER-verbatim bold labels were left untouched.
  6. 4.5 / 2.8 — Contraindication gate item trimmed: The “Populations who should avoid concentrated extract” item was compressed (“cirrhosis of any Child-Pugh class” → “cirrhosis (any Child-Pugh class)”, the two overlapping liver-injury-history clauses merged), preserving every population and threshold.
  7. 4.5 / 2.8 — Interaction gate wording tightened: “oral decongestants” → “decongestants” and “synephrine-containing supplements” → “synephrine supplements”; all named example drugs retained per 9.5.

Net effect: the rendered body dropped from 902 to 808 words. The residual bulk is content the checklist mandates — 18 benefit items (12.1/12.3), 11 risk items (13.1/13.3), 11 gate items (8.2/9.2 with example drug lists preserved under 9.5) and all 11 biomarker rows (14.2) — so it was condensed rather than removed.

Issues 05/08/2026 18:34

  1. 2.5 / 2.6 / 2.9 — Imperative brewing instructions: action_1_sub (line 450) reads “Brew at 70–80 °C for 2–3 minutes; cool below 60 °C before drinking”, which instructs the reader in the imperative instead of presenting the ER’s descriptive statements at lines 463 and 440.

Fixes 05/08/2026 18:34

  1. 2.5 / 2.6 / 2.9 — Imperative brewing instructions: Rewrote action_1_sub from “Brew at 70–80 °C for 2–3 minutes; cool below 60 °C before drinking.” to “Brewed at 70–80 °C for 2–3 minutes and cooled below 60 °C before drinking.”, removing the imperative address to the reader.